Rafael Fonseca, MD Mayo Clinic Scottsdale Interview Date: May 18, 2018 Summary Dr. Rafael Fonseca joins Myeloma Crowd Radio to share a new tool for myeloma patients called HealthTree. HealthTree can help myeloma patients find and understand personally relevant treatment options that can then be taken to their doctor for an informed clinic visit. HealthTree[...]

[...]

[...]

[...]

    Martin Kaiser, MD Institute of Cancer Research Interview Date: February 5, 2018   Summary Martin Kaiser, MD of the Institute of Cancer Research in the United Kingdom joins Myeloma Crowd Radio at ASH 2017 to discuss myeloma care in the United Kingdom and how the aggregation of myeloma genomic data from over 4,000[...]

Robert Z. Orlowski, MD MD Anderson Cancer Center Interview Date: January 5, 2018 Summary Much is happening in the world of myeloma. Where are we headed in 2018? Dr. Robert Z. Orlowski of the MD Anderson Cancer Center joins us to share the latest. He reviews a variety of treatment options for smoldering myeloma, emphasizes[...]

Irene Ghobrial, MD Dana Farber Cancer Institute Interview Date: September 27, 2017 Summary Myeloma patients hate the bone marrow biopsy, which can determine the level of tumor burden as well as the genetics of myeloma. These biopsies are a literal pain in the butt for patients who see them as a necessity to gain information[...]

Michael O’Dwyer, MD National University of Ireland Galway Interview Date: August 25, 2017 Summary Why does multiple myeloma become resistant to current treatments? Research has been done showing that sugar molecules can cover the surface of cancerous cells, hiding them from the immune system. The surface sugars, called sialic acids, can mark the cancer cells as[...]

Sagar Lonial, MD Winship Cancer Institute Interview Date: July 19, 2017 Summary Recent meetings held this summer had important updates in multiple myeloma therapy. Renown myeloma expert Sagar Lonial, MD of the Winship Cancer Institute joins Myeloma Crowd Radio to share the latest in developments for newly diagnosed, relapsed/refractory, elderly and high-risk patients.  He stressed[...]

[...]